Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|September 25, 2015
Ubl Named Next PhRMA President and CEO
Author(s)Pharmaceutical Technology Editors
Stephen J. Ubl to succeed John J. Castellani as the next president and chief executive officer of PhRMA.
Advertisement
The board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) on Sept. 25, 2015 named Stephen J. Ubl the next president and chief executive officer of the association. He succeeds John J. Castellani, who will be retiring at the end of the year.
Ubl joins PhRMA after more than 10 years as the president and CEO of the Advanced Medical Technology Association where he worked with patient advocacy organizations, providers, and public and private payers. He was a board member of the National Health Council.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement